Meeting News CoverageVideo

VIDEO: Some women with early-stage breast cancer can safely avoid adjuvant chemotherapy

NEW ORLEANS — Hatem Soliman, MD, assistant member of the women’s oncology and breast cancer department at Moffitt Cancer Center, discusses the implications of the results from the randomized phase 3 MINDACT trial, presented at the American Association for Cancer Research Annual Meeting.

Results showed a genomic test called MammaPrint can help predict which patients with early-stage breast cancer will derive the most benefit from adjuvant chemotherapy.

“There are women who are lymph node-positive who we would traditionally consider as being high-risk, but when they had a low-risk MammaPrint (test result), they did very well and had over a 95% chance of not having a recurrence of their disease,” Soliman told HemOnc Today. “Women with low-risk MammaPrint tests can likely safely avoid additional chemotherapy after their surgical treatment and still have excellent outcomes.”

See more from American Association for Cancer Research Annual Meeting